MedTrace Logo

Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT04852822 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2024-08-02

No results posted yet for this study

Summary

This study evaluates the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer that begin in cells of the immune system. CLL/SLL and the medications used to treat these conditions may change the way vaccines work in a patient's body. The purpose of this study is to find out if patients with CLL/SLL make antibodies, or have an immune response, to the SARS-CoV-2 vaccines. Information gained from this study may help researchers better understand how effective the vaccines work in preventing COVID-19 (coronavirus disease 2019) in patients with CLL and SLL.

Conditions

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

OTHER

Electronic Health Record Review

Medical records are reviewed

Sponsors & Collaborators

Principal Investigators

  • Chaitra S. Ujjani, MD · Fred Hutch/University of Washington Cancer Consortium

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-18
Primary Completion
2023-01-01
Completion
2024-07-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04852822 on ClinicalTrials.gov